Document Outlines Key Clinical Considerations About QTc Prolongation and Psychotropics
Psychiatrists should be prepared to analyze the risks and benefits of psychotropic medications that may affect QTc prolongation and should be proficient at interpretation of ECG readings.
Prolongation of the QT interval on the 12-lead electrocardiogram (ECG) is a primary drug-safety benchmark used by the Food and Drug Administration when assessing medications for cardiac risk. A variety of mathematical formulae, programmed into ECG machines, are used to arrive at a corrected QT interval (QTc), which corrects for heart rate extremes (higher or lower).
The use of certain psychotropic medications can increase the risk of QTc prolongation and Torsades de pointes (TdP), a potentially fatal ventricular arrhythmia. Over the past decade, physicians have become more aware of the potential for TdP with the use of psychotropic medications, but there is significant variability in practice and policy at the individual and institutional levels.
To address this gap, the APA Council on Consultation-Liaison Psychiatry’s Workgroup on QTc Prolongation and Psychotropic Medications created a comprehensive set of clinical considerations, which are endorsed by the American College of Cardiology. They are posted as a resource document on APA’s website and published in the March American Journal of Psychiatry.
There is not an absolute QTc value at which a psychotropic medication should not be used. A pretreatment QTc greater than 500 ms should trigger a comprehensive risk-benefit analysis, weighing the risk of TdP with the benefits of proceeding with the medication. When the treatment team is considering the withholding of a psychotropic medication, the team should carefully consider the impact of psychiatric decompensation and/or failure to control high-risk psychopathology.
In patients with significant cardiac risk factors, psychotropic medications with a known risk to prolong the QTc interval or those with a regulatory warning should be avoided when relatively safer alternatives are available. Many risk factors other than medications—both modifiable and nonmodifiable—can increase the risk of TdP independently. Thus, when conducting a risk-benefit analysis, psychiatrists must be aware that combinations of these risk factors, including co-administration of two or more QTc-prolonging medications, can create cumulative risk.
Unfortunately, the quality of studies measuring the level of risk associated with medications is variable. Moreover, there is no uniformity among various professional guidelines, FDA drug safety recommendations, and those of other international regulatory bodies.
To further complicate matters, the most commonly used formula for measuring QT heart-rate correction—the Bazett formula, which is programmed into most ECG machines—is known to be unreliable. Evidence is mixed about which formula is best, but most other formulae (Fridericia, Framingham, Hodges, Nomogram) have proven more reliable than Bazett.
Ideally, psychiatrists should be proficient at ECG interpretation and thoughtful about the use of recommended heart-rate correction formulae. The absence of a cardiologist (or physician from any other medical specialty) to read an ECG should not preclude obtaining one when it is indicated.
Routine cardiology consultation is not indicated when prescribing QTc interval–prolonging medications to a patient without cardiac risk factors. However, when significant cardiac disease and/or other risk factors for QTc interval prolongation are present, cardiology input should be considered.
Psychiatrists should feel empowered to fully utilize their skills as physicians first, recognizing that they have the ability and authority to make complex psychopharmacologic treatment decisions. Psychiatrists should and will be looked to as the experts on complex psychopharmacology and must be comfortable understanding associated levels of cardiac risk. ■
“QTc Prolongation and Psychotropic Medications” is posted here.
Biographies
Margo Funk, M.D., M.A., is chair of APA’s Council on Consultation-Liaison Psychiatry’s Workgroup on QTc Prolongation and Psychotropic Medications and program director of the Harvard South Shore Psychiatry Residency Training Program at the VA Boston Healthcare System. Richard Kovacs, M.D., is the immediate past president of the American College of Cardiology, the Q.E. and Sally Russell Professor of Cardiology at Indiana University School of Medicine, the cardiology service line leader of IU Health, and the clinical director of the Krannert Institute of Cardiology.
Information & Authors
Information
Published In
Psychiatric News
History
Published online: 28 April 2020
Published in print: April 18, 2020 - May 1, 2020
Keywords
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
Get Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).